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A rapid and sensitive liquid chromatographyetandem mass spectrometry method was
developed and validated for the quantification of cyclobenzaprine in dog plasma. After
extracted with organic solvent, post-treatment samples were separated on an Agela C18
column interfaced with a triple quadrupole tandem mass spectrometer in positive elec-
trospray ionization mode. Multiple reaction monitoring was performed using the transi-
tions of m/z 276.2 / 216.1 and m/z 325.1 / 109.0 to quantify cyclobenzaprine and
escitalopram (internal standard), respectively. The mobile phase consisted of acetonitrile:
5 mM ammonium acetate: formic acid (90:10:0.01, v/v/v) at a flow rate of 0.3 ml/min. The
total analysis time was 2.4 min. The method was linear over the concentration range of
0.0200e10.0 ng/ml. The intra- and inter-day precision was within 12.8% in terms of relative
standard deviation (RSD%) and the accuracy within 5.6% in terms of relative error. This
method was successfully applied in a pharmacokinetic study of extended-release cyclo-
benzaprine in dogs.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Cyclobenzaprine (Fig. 1), 3-(5H-dibenzo[a,d]cyclohepten-5-
ylidene)-N,N-dimethyl-1-propanamine, is a centrally acting; fax: þ86 24 23986250.
an).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univskeletal muscle relaxant shown to be effective for relief of
musculoskeletal pain Refs. [1e3]. The exact mechanism of
action is unknown, but it is presumed to work at the brain
stem, reducing tonic somatic motor activity at both g- and a-
motor neuron systems [4,5]. Cyclobenzaprine has been usedsity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
Fig. 1 e Structures of cyclobenzaprine (A) and escitalopram (IS, B).
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than 30 years in clinic [6,7].
In previous studies, differentmethods, including thin layer
chromatography (TLC) [8], gas chromatography (GC) equipped
with nitrogen selective detector or flame ionization detector
[9,10], high performance liquid chromatography (HPLC) with
ultraviolet absorbance detection (UV) [11,12], and liquid
chromatographyetandem mass spectrometry (LCeMS/MS)
with atmospheric pressure chemical ionization (APCI) [12] or
eletrospray ionization source (ESI) [13,14], were developed for
quantitative analysis of cyclobenzaprine in biological sam-
ples. The TLC, GC and HPLC-UVmethods were not suitable for
the quantification of cyclobenzaprine following a low oral
dosage because of long analysis time and poor sensitivity. The
reported LCeMS/MS methods were rapid and sensitive with a
run-time of 3e5 min and the lowest limit of quantification
(LLOQ) of 0.1e0.5 ng/ml; however, they suffered from tedious
sample preparation [13] or used a bulk plasma volume of 1 ml
[12,14]. Xiang et al. established an LCeESI-MS/MS method to
determine cyclobenzaprine using a plasma volume of 0.5 ml
with an LLOQ of 0.049 ng/ml [15]. They separated cyclo-
benzaprine on an Ultimate XB-CN column. Cyano column is
not used as commonly as C18 column in routine bioanalysis
and its service life is easily decreased in reversed phase
chromatography. Therefore, in this paper, we developed a
rapid and sensitive LCeMS/MS method to determine cyclo-
benzaprine in dog plasma with a C18 column in a run-time of
2.4 min. A 0.4 ml aliquot of plasma was used in the present
method and the LLOQ was 0.0200 ng/ml. The method was
successfully applied to a pharmacokinetic study of cyclo-
benzaprine in beagle dogs.2. Materials and methods
2.1. Chemicals and materials
Cyclobenzaprine (99.6% purity) and escitalopram (99.7% pu-
rity) were obtained from Suizhou Jiake Biomedicine Co.
(Hubie, China) and National Institute for the Control of Phar-
maceutical and Biological Products (Beijing, China), respec-
tively. Cyclobenzaprine extended-release capsules (AMRIX)
were supplied by Cephalon Inc (PA, USA). HPLC-grade aceto-
nitrile was purchased from Dikma Technology (CA, USA).Distilled water, prepared from demineralized water, was used
throughout the study. All other chemicals and solvents were
of analytical grade or better and used without further
purification.
2.2. Instrument and LCeMS/MS conditions
2.2.1. Chromatographic conditions
Chromatographic separation was performed on an Agela C18
column (50  2.1 mm i.d., 3.0 mm) using an Agilent 1290 LC
system (Agilent, CA, USA). The column temperature was kept
at 30 C. The mobile phase consisted of acetonitrile: 5 mM
ammonium acetate: formic acid (90:10:0.01, v/v/v) at a flow
rate of 0.3 ml/min. The injection volume was 5 ml.
2.2.2. Mass spectrometric conditions
An API 4000 triple quadrupole tandem mass spectrometer
(Applied Biosystem/MDS SCIEX, CA, USA) with electrospray
source (ESI) was operated in positive ion mode. The quantifi-
cation was performed using multiple reaction monitoring
(MRM) method with the transitions of m/z 276.2/ 216.0 for
cyclobenzaprine and m/z 325.1 / 109.0 for escitalopram
(internal standard; IS). The main working parameters were
set as follows: ionspray voltage, 4.0 kV; ion source tempera-
ture, 400 C; gas1, 40 psi; gas2, 40 psi; curtain gas, 20 psi.
Analyte concentrations were determined using the software
Analyst 1.5.
2.3. Preparation of calibration standards and quality
control samples
Stock solutions of cyclobenzaprine and escitalopram (IS) were
prepared in acetonitrile at a concentration of 500 mg/ml,
respectively. A series of cyclobenzaprine working standard
solutions with concentrations in the range of 0.200e100 ng/ml
were obtained by further dilution of the stock solution with
acetonitrile. The IS working solution was diluted with aceto-
nitrile to a final concentration of 50.0 ng/ml. All solutionswere
stored at 20 C until analysis and they were found to be
stable for at least 30 d (data not shown).
Plasma calibration standards of cyclobenzaprine at con-
centrations of 0.0200, 0.0400, 0.200, 1.00, 5.00 and 10.0 ng/ml
were prepared as follows: a 40 ml aliquot of cyclobenzaprine
working standard solutions was spiked into an 8-ml glass
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stream. A 400 ml aliquot of blank plasma was then added to
each tube. Quality control (QC) samples of 0.0400, 0.800 and
8.00 ng/ml were prepared in the same way as calibration
standards. Additional validation QCs were prepared at
0.0200 ng/ml to test LLOQ. The spiked plasma (calibrators and
QCs) were treated according to the sample preparation
described below.2.4. Sample preparation
To a 400 ml aliquot of each plasma sample, 40 ml of IS solution
(50.0 ng/ml escitalopram inacetonitrile) and40 ml of 1Msodium
carbonate were added and vortex-mixed for 10 s. After the
addition of 3 ml of n-hexane: dichloromethane: isopropanol
(2:1:0.1, v/v/v), the samplewas placedon a reciprocating shaker
for 10 min at 120 rpm, followed by centrifugation at 2110 g for
5 min. The organic layer was separated and evaporated to
dryness at 40 C under an air stream. The residue was recon-
stituted in 100 ml of the mobile phase and 5 ml was injected for
LCeMS/MS analysis.2.5. Method validation
The validation process was conducted according to Guidance
for Industry Bioanalytical Method Validation, recommended
by FDA [16].
Specificity of the method was evaluated by analyzing six
different blank plasma samples to investigate the potential
interferences at the retention times for the analyte and IS.
The linearity of the method was assessed by processing (in
duplicate) a six-point calibration curve over the concentration
range of 0.0200e10.0 ng/ml. The calibration curves were con-
structed by plotting the peak area ratios of the analyte to IS
versus the nominal concentrations of the analyte by weighted
(1/x2) least-squares linear regression. The LLOQwas defined as
the lowest plasma concentration in the calibration curve
yielding a signal-to-noise ratio of at least 10.
The precision and accuracy were evaluated by analyzing
QCs at plasma concentrations of 0.0200 (LLOQ), 0.0400, 0.800
and 8.00 ng/ml in six replicates on three separated days. The
criteria for acceptability of the data included accuracy within
15% relative error (%RE) of the nominal values and a preci-
sion of within 15% relative standard deviation (%RSD) except
for LLOQ at which both precision and accuracy were within
20%.
The matrix effect and extraction recovery for cyclo-
benzaprine and IS were evaluated by assaying three groups of
samples: neat standard solutions of cyclobenzaprine and IS
(group 1), blank plasma extracts from six different dogs spiked
with cyclobenzaprine and IS after liquideliquid extraction
(group 2), and plasma extracts spiked with cyclobenzaprine
and IS before extraction (group 3). Samples of each groupwere
prepared at three cyclobenzaprine levels of 0.0400, 0.800 and
8.00 ng/ml. The matrix effects were calculated as the ratio of
peak area of an analyte spiked post-extraction (group 2) to its
mean peak area from neat solution (group 1). The variability
(RSD) of matrix effect at each concentration level should be
less than 15% [17]. The recovery was calculated as the ratio ofthe peak area of an analyte spiked prior to extraction (group 3)
to its mean peak area after extraction (group 2).
The stability of cyclobenzaprine in dog plasma was
assessed by analyzing triplicates of QCs at 0.0400 and 8.00 ng/
ml, whichwere exposed to different temperatures and storage
conditions. These QCs were analyzed after storage at room
temperature for 4.0 h (bench-top), at 70 C for 24 d, after
three freezeethaw cycles at 70 C and after transportation
with dry ice for 2.0 h. The stability of cyclobenzaprine and IS in
the injection solvent was determined periodically by re-
injecting the processed QCs for up to 24 h (at room tempera-
ture) after the initial injection. Samples were considered sta-
ble if assay values were within the acceptable limits of
accuracy (15% RE) and precision (15% RSD).
The dilution integrity experiment was performed with an
aim to validate the dilution test to be carried out on higher
analyte concentrations above upper limit of quantification
(ULOQ), whichmay be encountered during real subject sample
analysis. Dilution integrity experiment was carried out at 4
times ULOQ concentrations in six replicates. Samples at 4
times ULOQ concentrationwere 5 times dilutedwith drug-free
plasma. Their concentrations were calculated by applying the
dilution factor 5 against the freshly prepared calibration
curve. The criteria for acceptability of the data included ac-
curacy within 15% RE and precision within 15% RSD.
2.6. Pharmacokinetic study
Animal experiments were performed in accordance with the
guidelines of the Experimental Animal Care and Use Com-
mittee of Shenyang Pharmaceutical University (Shenyang,
China). Six beagle dogs (9.73  0.31 kg, half male and half fe-
male) were supplied by Shenyang Kangping Laboratory Ani-
mal Institute (Shenyang, China). They were housed under
standard conditions and had ad libitum access to water. After
fasted for 12 h, dogs were given an oral dose of 15 mg
extended-release cyclobenzaprine hydrochloride. Blood sam-
ples were collected into heparinized tubes before (0 h) and at
0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, 14, 16, 18, 20, 22, 24, 36 and
48 h after administration. Plasma was separated by centrifu-
gation at 2110 g for 5 min and stored at 70 C until analysis.
Pharmacokinetic parameters of cyclobenzaprine were
calculated by non-compartmental method using DAS 3.2
pharmacokinetic program (Chinese Pharmacology Society).3. Results and discussion
3.1. Method development
An LCeMS/MS method with APCI ionization source was re-
ported for the quantification of cyclobenzaprine using 1 ml of
plasma with an LLOQ of 0.1 ng/ml [12]. ESI interface is used
more widely than APCI interface in bioanalysis because most
of polar and non-polar analytes can be ionized in ESI source. In
the present study, we found that cyclobenzaprine was easily
ionized in ESI interface to form protonated ion of [M þ H]þ at
m/z 276.2 and its signal intensity in ESI sourcewas higher than
that in APCI source. Therefore, ESI was chosen as the ioniza-
tion source in this method. After the instrument parameters
Fig. 2 e Full scan MS/MS spectra of [M D H]D of
cyclobenzaprine (A) and escitalopram (IS, B).
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325.1/ 109.0 were used to quantify cyclobenzaprine and IS,
respectively (Fig. 2).
To improve the sensitivity of the method, various chro-
matographic conditions were tested. Xiang et al. separated
cyclobenzaprine in human plasma on a cyano column in
reversed phase chromatography [15]. Because cyano bonds
hydrolyze inwater, the quality of cyano column becomes poor
easily when it is used in reversed phase chromatographicFig. 3 e Representative MRM chromatograms for cyclobenzaprin
samples. Panel A: a blank plasma sample; panel B: a blank plas
C: a dog plasma sample collected at 10 h after drug administrasystem. An Agela C18 column packed with 3.0 mm particles
was used in the present method. Compared with columns
with bigger particle size (5.0 mm), the peak width of cyclo-
benzaprine was thinner on this column and signal-to-noise
ratio was increased about 3 times. Additionally, the use of
ammonium acetate as mobile phase decreased the tailing of
the peak obviously and made the peak sharper. After careful
comparison of the composition of mobile phase, eventually, a
mixture of acetonitrile: 5 mM ammonium acetate: formic acid
(90:10:0.01, v/v/v) was adopted to achieve good sensitivity and
shorten running time. In this chromatographic condition, the
retention times of cyclobenzaprine and escitalopram (IS) were
1.9 and 1.7 min, respectively. The total run-time was 2.4 min.
Compared with previously reported LCeESI-MS/MS methods
[13e15], this method was more sensitive with an LLOQ at
0.0200 ng/ml by using smaller sample volume (0.4 ml) and the
analysis time was shorter.3.2. Method validation
3.2.1. Specificity
Potential interference from endogenous substances was
investigated. Representative chromatograms obtained from
blank plasma, blank plasma spiked with cyclobenzaprine at
the LLOQ, and a dog plasma sample taken at 10 h after an oral
administration of 15 mg extended-release cyclobenzaprine
hydrochloride are shown in Fig. 3. No interfering peaks with
cyclobenzaprine or IS were observed which indicated that the
developed method was specific for the analysis of cyclo-
benzaprine in dog plasma (Fig. 4).
3.2.2. Linearity and LLOQ
Linearity of the method was observed in cyclobenzaprine
concentration range of 0.0200e10.0 ng/ml. The representative
calibration curve was y ¼ 1.38  101x þ 2.08  104, and the
correlation coefficient was higher than 0.995. The LLOQ was
confirmed to be 0.0200 ng/ml, at which the relative error wase (peak I) and escitalopram (IS, peak II) in dog plasma
ma sample spiked with cyclobenzaprine at the LLOQ; panel
tion.
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Fig. 4 e Mean plasma concentrationetime curve of
cyclobenzaprine in beagle dogs after an oral
administration of 15 mg extended-release cyclobenzaprine
hydrochloride (n [ 6 per time point). Values are
represented as mean ± SD.
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(Table 1).
3.2.3. Precision and accuracy
Table 1 summarizes the results for intra- and inter-day pre-
cision and accuracy for cyclobenzaprine measured by QCs.
The intra- and inter-day precisions were all below 15% with a
maximum RSD of 12.8%, and a maximum RE of 5.6% for ac-
curacy was calculated.
3.2.4. Recovery and matrix effect
The recoveries of cyclobenzaprine extracted from plasma
were 90.0  4.5, 101.1  3.1 and 93.0  2.7% at the concentra-
tions of 0.0400, 0.800 and 8.00 ng/ml, respectively. The recov-
ery of IS at 5.0 ng/ml was 92.3  4.2%. The matrix effects of
cyclobenzaprine were in the range of 86.5e89.7% with RSD
values below 8.5% at concentrations of 0.0400, 0.800 and
8.00 ng/ml. The matrix effect of IS was 96.3% and the RSD
value was 3.6%. These results indicated that the effect of
matrix on the determination of cyclobenzaprine could be
ignored.Table 1 e Precision and accuracy of the LCeMS/MS
method to determine cyclobenzaprine in dog plasma (in 3
consecutive days, six replicates for each day).
Concentration (ng/ml) Precision (RSD%)a Accuracyb
Added Measured Intra-day Inter-day (RE%)
0.0200 0.0218  0.0027 6.6 4.3 8.8
0.0400 0.0418  0.0034 8.6 2.0 4.4
0.800 0.845  0.084 9.6 12.8 5.6
8.00 7.99  031 3.6 3.9 0.1
a Expressed as RSD%: (SD/mean)  100.
b Calculated as RE%: (measured concentration-added concentra-
tion)/(added concentration)  100.3.2.5. Stability
Table 2 contains the results of investigations into the stability
of cyclobenzaprine under the various conditions tested
throughout the validation process. The tests were designed to
cover anticipated conditions which might be encountered
during sample handling and processing. The results indicated
the stability of cyclobenzaprine in plasma after storage at
room temperature for 4.0 h (bench-top), at 70 C for 24 d,
after three freezeethaw cycles at 70 C, during trans-
portation for 2.0 h (dry ice) and in processed samples at room
temperature for 24 h.
3.2.6. Dilution integrity
During themethod development, saturated signal response of
cyclobenzaprine was observed above the plasma concentra-
tion of 15 ng/ml. Preliminary pharmacokinetic study of
cyclobenzaprine indicated that the concentrations of some
plasma samples collected after administration were higher
than 20 ng/ml. Basing on these results, four-fold dilution
integrity was hence tested in the present study as described in
Experimental. The mean back-calculated concentrations for
1/5 dilution samples were within 4.1%RE of the nominal
concentration with an RSD of 6.9%.
3.3. Pharmacokinetic study
The validated LCeMS/MS method was successfully applied to
the pharmacokinetic study of cyclobenzaprine in beagle dogs
after an oral administration of 15 mg extended-release
cyclobenzaprine hydrochloride. The mean plasma concen-
tration versus time profile of cyclobenzaprine is shown in
Fig. 4 and the main pharmacokinetic parameters are pre-
sented in Table 3.
Cyclobenzaprine reached the peak plasma concentration
(Cmax) at approximately 3.50 h. It eliminated slowly from the
plasma with a mean elimination half-time (T1/2) of 9.70 h.
Marked interanimal variability was found in the pharmaco-
kinetic profile of cyclobenzaprine in beagle dogs after drug
administration. The values of Cmax varied from 2.19 to 32.9 ng/
ml. The area under curves (AUC0et) in plasmawas in the range
from 24.4 to 33.9 ng$h/ml. Significant individual deference
was also observed in the pharmacokinetics ofTable 2 e Summary of stability of cyclobenzaprine under
various storage in plasma (n[ 3).
Storage condition Concentration
(ng/ml)
RSD (%) RE (%)
Added Measured
Room temperature
for 4 h (Bench-top)
0.0400 0.0403  0.0029 7.2 2.8
8.00 8.03  0.22 2.8 0.4
Frozen (70 C) for
24 d
0.0400 0.0428  0.0041 9.5 7.1
8.00 8.20  0.17 2.1 2.5
Three freezeethaw
cycles at 70 C
0.0400 0.0416  0.0012 2.9 4.1
8.00 7.96  0.20 2.5 0.5
Transportation for
2 h (dry ice)
0.0400 0.0403  0.0009 2.3 0.7
8.00 7.87  0.13 1.6 1.6
Post-pretreatment at
room temperature
for 24 h
0.0400 0.0418  0.0031 7.5 4.4
8.00 7.93  0.35 4.4 0.8
Table 3 e Pharmacokinetic parameters of
cyclobenzaprine after an oral administration of
15 mg extended-release cyclobenzaprine
hydrochloride.
Parameters Mean  SD
Cmax (ng/ml) 11.9  11.2
Tmax (h) 3.50  0.55
T1/2 (h) 9.70  9.73
AUC0et (ng h/ml) 122  116
AUC0eN (ng h/ml) 123  116
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common tablet and extended-release formulation [13e15],
although it was not as obviously as that in dogs.4. Conclusion
A rapid and sensitive LCeESI-MS/MS method has been
developed and validated for the analysis of cyclobenzaprine in
dog plasma. The separation of cyclobenzaprine was carried
out on a C18 column. This method showed high throughput
(2.4 min each sample) and good sensitivity with an LLOQ of
0.0200 ng/ml. This method was successfully applied to char-
acterize the pharmacokinetics of extended-release cyclo-
benzaprine hydrochloride in beagle dogs.r e f e r e n c e s
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